All In Biotech

Drug Trial Radar · NCT05930119

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Sep 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Mar 17, 2023

Primary completion

Aug 28, 2023

Study completion Aug 28, 2023

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Jul 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

  • HMPL-453Drug

    300 mg HMPL-453

  • RabeprazoleDrug

    20 mg of rabeprazole will be administered by mouth once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter for HMPL-453: AUC0-tTime frame: Day 1 to Day 33
  2. PK parameter for HMPL-453: AUC0-infTime frame: Day 1 to Day 33
  3. PK parameter for HMPL-453: CmaxTime frame: Day 1 to Day 33

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.